Evidence map›Paper›PMID 25715772›Full record

ArticleCancer research and treatment2016

Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea.

Jaemin Jo, Jung Ho Kim, Ji Young Kim, Changlim Hyun, Jiyoung Rhee, Jungmi Kwon, Sanghoon Han, Wookun Kim

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jaemin JoDepartment of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea.
Jung Ho KimDepartment of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Ji Young KimDepartment of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea.
Changlim HyunDepartment of Pathology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea.
Jiyoung RheeDepartment of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea.
Jungmi KwonDepartment of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea.
Sanghoon HanDepartment of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea.
Wookun KimDepartment of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pazopanib is a potent multitargeted tyrosine kinase inhibitor that has been shown to have good efficacy in patients with renal cell carcinoma. A previous phase II trial demonstrated that short-term pazopanib administration was generally well tolerated and showed antitumor activity in patients with early-stage non-small cell lung cancer. Herein, we report on the case of a 66-year-old man with simultaneous metastatic squamous cell carcinoma of the lung and renal cell carcinoma who was treated with pazopanib. The patient showed an unexpected partial response and experienced a 10-month progression-free survival without significant toxicity. To the best of the authors' knowledge, this is the first report of pazopanib treatment in a non-small cell lung cancer patient in Korea. The results in this patient suggest that pazopanib may be a valid treatment option for advanced non-small cell lung cancer.

Indexed as

AgedCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellDisease-Free SurvivalHumansIndazolesKidney NeoplasmsLung NeoplasmsMaleProtein-Tyrosine KinasesPyrimidinesRepublic of KoreaSulfonamidesTreatment OutcomeIndazolespazopanibProtein-Tyrosine KinasesPyrimidinesSulfonamidesDrug therapyLung neoplasmsPazopanibTyrosine kinase inhibitor

Identifiers

PMID25715772
PMCPMC4720062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.